Aromatase inhibitors and bone health in women with breast cancer.
Chien
Amy Jo
AJ
Department of Internal Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. ajchien@partners.org
Goss
Paul E
PE
D015502:Absorptiometry, Photon; D000465:Algorithms; D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D008019:Life Style; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000517:prevention & control*; D011159:Population Surveillance; D012307:Risk Factors; D014230:Triazoles / Q000627:therapeutic use
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004164:Diphosphonates; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; C056516:exemestane